Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma

Abstract excerpt

BRAF-activating mutations have been detected in nearly all craniopharyngiomas of the papillary subtype,1 with interesting implications for patients with suboptimal tumor control. Here we report that combined treatment with BRAF and MEK inhibitors resulted in major clinical benefit in the case of a patient with a BRAF V600E-mutant papillary craniopharyngioma rapidly progressing after surgery. A 55-year-old woman...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related Molecular Pathways
• Share to Melanoma and MAPK Pathways
• Share to Retinoids in leukemia and cellular processes